Compare BHE & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHE | GRDN |
|---|---|---|
| Founded | 1979 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Retail-Drug Stores and Proprietary Stores |
| Sector | Technology | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1990 | 2024 |
| Metric | BHE | GRDN |
|---|---|---|
| Price | $44.39 | $31.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $46.50 | $32.00 |
| AVG Volume (30 Days) | ★ 306.0K | 295.4K |
| Earning Date | 01-28-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.02 | 0.28 |
| Revenue | ★ $2,611,664,000.00 | $1,389,638,000.00 |
| Revenue This Year | $0.82 | $19.50 |
| Revenue Next Year | $5.19 | $0.48 |
| P/E Ratio | ★ $43.23 | $111.74 |
| Revenue Growth | N/A | ★ 18.68 |
| 52 Week Low | $30.73 | $17.78 |
| 52 Week High | $50.26 | $37.43 |
| Indicator | BHE | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 64.61 |
| Support Level | $43.70 | $29.73 |
| Resistance Level | $49.89 | $31.50 |
| Average True Range (ATR) | 1.46 | 1.08 |
| MACD | -0.48 | 0.14 |
| Stochastic Oscillator | 11.22 | 93.33 |
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.